ProQR Therapeutics NV reports results for the quarter ended in December - Earnings Summary

ProQR Therapeutics NV

24/02/2022 19:39

* ProQR Therapeutics NV  PRQR.OQ  reported a quarterly
adjusted
loss of 26 cents​​ per share for the quarter ended in December.
The mean expectation of seven analysts for the quarter was for a
loss of 19 cents per share.
    * Revenue rose 68.2% to €444.00 thousand from a year ago; 
analysts expected €394.20 thousand. 
    * ProQR Therapeutics NV's reported EPS for the quarter was a
loss
of 26 cents​.
    * The mean earnings estimate of analysts had fallen by
about 4.8%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * ProQR Therapeutics NV shares had fallen by 86.6% this
quarter.
    * The company reported a quarterly loss of €18.22 million.
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $7.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell." 

This summary was machine generated February 24 at 07:39 p.m.
 ​All figures in euros unless otherwise stated